US patent for Anadys Pharma covering setrobuvir PBR Staff WriterPublished 02 June 2011 The US Patent and Trademark Office has granted Patent No 7,939,524 to Anadys Pharmaceuticals’ setrobuvir (ANA598), a Direct-Acting Antiviral (DAA) in development for chronic hepatitis C virus infection (HCV).
The patent recognizes the company's intellectual property rights to the composition of matter and methods of use for setrobuvir and related compounds.
Setrobuvir, which has received fast track status from the US Food and Drug Administration, is an HCV RNA polymerase inhibitor that belongs to a chemical class referred to as non-nucleosides.
It has a well-characterized safety database in which more than 150 subjects have received the agent to date.
In the ongoing Phase IIb study, setrobuvir is being tested in combination with Pegasys and Copegus in both treatment-naive patients and patients who failed a prior course of therapy with interferon and ribavirin.
The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.
Anadys expects to receive antiviral response data through 12 weeks for all patients, including the 8 week time point used for response-guided therapy in treatment-naive patients, in the third quarter of 2011.
Antiviral response data through 24 weeks are expected in the fourth quarter of 2011. 作者: StephenW 时间: 2011-6-2 19:53